Combination of granulocyte-monocyte apheresis and ustekinumab: Multicentre and retrospective study

Gastroenterol Hepatol. 2024 Dec;47(10):502195. doi: 10.1016/j.gastrohep.2024.502195. Epub 2024 May 6.
[Article in English, Spanish]

Abstract

Objective: Granulocyte-monocyte apheresis (GMA) has shown to be safe and effective in ulcerative colitis (UC), also in combination with biologics, mainly with anti-TNF. The aim of this study was to evaluate the efficacy and safety of combining GMA after primary non-response (PNR) or loss of response (LOR) to ustekinumab (UST) in patients with UC.

Patients and methods: A retrospective study was performed in 12 IBD Units, including all patients with refractory UC or unclassified IBD (IBD-U) who received combined GMA plus UST. The number and frequency of GMA sessions, filtered blood volume and time of each session were registered. Efficacy was assessed 1 and 6 months after finishing GMA by partial Mayo score, C-reactive protein (CRP) and fecal calprotectin (FC). Descriptive statistics and non-parametric tests were used in the statistical analysis.

Results: Seventeen patients were included (15 UC, 2 IBD-U; median age 47 years [IQR, 35-61]; 59% male; 53% E3). Most patients (89%) had prior exposure to anti-TNF agents and 53% to vedolizumab; 65% were also receiving steroids at baseline. Median partial Mayo score at baseline was 6 (IQR, 5-7) and it significantly decreased after 1 and 6 months (p=0.042 and 0.007, respectively). Baseline FC significantly decreased after 6 months (p=0.028) while no differences were found in CRP. During follow-up, 18% patients started a new biologic therapy and 12% required surgery; 64% of patients under steroids were able to discontinue them. Adverse events were reported in one patient.

Conclusion: GMA can recapture the response to UST in selected cases of UC after PNR or LOR to this drug.

Keywords: Aféresis de granulocitos-monocitos; Colitis ulcerosa; Enfermedad inflamatoria intestinal; Granulocyte–monocyte apheresis; Inflammatory bowel disease; Ulcerative colitis; Ustekinumab.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Blood Component Removal / methods
  • C-Reactive Protein / analysis
  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / therapy
  • Combined Modality Therapy
  • Female
  • Granulocytes*
  • Humans
  • Leukapheresis / methods
  • Male
  • Middle Aged
  • Monocytes*
  • Retrospective Studies
  • Treatment Outcome
  • Ustekinumab* / therapeutic use

Substances

  • Ustekinumab
  • C-Reactive Protein